Cargando…

Identification of compound heterozygous patients with primary hyperoxaluria type 1: clinical evaluations and in silico investigations

BACKGROUND: Primary hyperoxaluria type 1 (PH1) is an autosomal recessive inherited disorder of glyoxylate metabolism in which excessive oxalates are formed by the liver and excreted by the kidneys. Calcium oxalate crystallizes in the urine, leading to urolithiasis, nephrocalcinosis, and consequent r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanoun, Houda, Jarraya, Faiçal, Maalej, Bayen, Lahiani, Amina, Mahfoudh, Hichem, Makni, Fatma, Hachicha, Jamil, Fakhfakh, Faiza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625645/
https://www.ncbi.nlm.nih.gov/pubmed/28969594
http://dx.doi.org/10.1186/s12882-017-0719-y
_version_ 1783268420664426496
author Kanoun, Houda
Jarraya, Faiçal
Maalej, Bayen
Lahiani, Amina
Mahfoudh, Hichem
Makni, Fatma
Hachicha, Jamil
Fakhfakh, Faiza
author_facet Kanoun, Houda
Jarraya, Faiçal
Maalej, Bayen
Lahiani, Amina
Mahfoudh, Hichem
Makni, Fatma
Hachicha, Jamil
Fakhfakh, Faiza
author_sort Kanoun, Houda
collection PubMed
description BACKGROUND: Primary hyperoxaluria type 1 (PH1) is an autosomal recessive inherited disorder of glyoxylate metabolism in which excessive oxalates are formed by the liver and excreted by the kidneys. Calcium oxalate crystallizes in the urine, leading to urolithiasis, nephrocalcinosis, and consequent renal failure if treatment is not initiated promptly. Mutations in the AGXT gene which encodes the hepatic peroxisomal enzyme alanine:glyoxylate aminotransferase are responsible of PH1. In the present work, we aimed to analyze AGXT gene and in silico investigations performed in four patients with PH1 among two non consanguineous families. METHODS: Exhaustive gene sequencing was performed after PCR amplification of coding exons and introns boundaries. Bioinformatic tools were used to predict the impact of AGXT variants on gene expression as well as on the protein structure and function. RESULTS: Direct sequencing of all exons of AGXT gene revealed the emergence of multiple mutations in compound heterozygous state in the two studied families. Two patients were compound heterozygous for the c.731 T > C, c.32C > T, c.1020A > G and c.33_34insC and presented clinically with recurrent urinary tract infection, multiple urolithiasis and nephrocalcinosis under the age of 1 year and a persistent hyperoxaluria at the age of diagnosis. The two other patients presenting a less severe phenotypes were heterozygous for c.731 T > C and homozygous for the c.32C > T and c.1020A > G or compound heterozygous for c.26C > A and c.65A > G variants. CONCLUSION: In Summary, we provided relevance regarding the compound heterozygous mutations in non consanguineous PH1 families with variable severity.
format Online
Article
Text
id pubmed-5625645
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56256452017-10-12 Identification of compound heterozygous patients with primary hyperoxaluria type 1: clinical evaluations and in silico investigations Kanoun, Houda Jarraya, Faiçal Maalej, Bayen Lahiani, Amina Mahfoudh, Hichem Makni, Fatma Hachicha, Jamil Fakhfakh, Faiza BMC Nephrol Research Article BACKGROUND: Primary hyperoxaluria type 1 (PH1) is an autosomal recessive inherited disorder of glyoxylate metabolism in which excessive oxalates are formed by the liver and excreted by the kidneys. Calcium oxalate crystallizes in the urine, leading to urolithiasis, nephrocalcinosis, and consequent renal failure if treatment is not initiated promptly. Mutations in the AGXT gene which encodes the hepatic peroxisomal enzyme alanine:glyoxylate aminotransferase are responsible of PH1. In the present work, we aimed to analyze AGXT gene and in silico investigations performed in four patients with PH1 among two non consanguineous families. METHODS: Exhaustive gene sequencing was performed after PCR amplification of coding exons and introns boundaries. Bioinformatic tools were used to predict the impact of AGXT variants on gene expression as well as on the protein structure and function. RESULTS: Direct sequencing of all exons of AGXT gene revealed the emergence of multiple mutations in compound heterozygous state in the two studied families. Two patients were compound heterozygous for the c.731 T > C, c.32C > T, c.1020A > G and c.33_34insC and presented clinically with recurrent urinary tract infection, multiple urolithiasis and nephrocalcinosis under the age of 1 year and a persistent hyperoxaluria at the age of diagnosis. The two other patients presenting a less severe phenotypes were heterozygous for c.731 T > C and homozygous for the c.32C > T and c.1020A > G or compound heterozygous for c.26C > A and c.65A > G variants. CONCLUSION: In Summary, we provided relevance regarding the compound heterozygous mutations in non consanguineous PH1 families with variable severity. BioMed Central 2017-10-02 /pmc/articles/PMC5625645/ /pubmed/28969594 http://dx.doi.org/10.1186/s12882-017-0719-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kanoun, Houda
Jarraya, Faiçal
Maalej, Bayen
Lahiani, Amina
Mahfoudh, Hichem
Makni, Fatma
Hachicha, Jamil
Fakhfakh, Faiza
Identification of compound heterozygous patients with primary hyperoxaluria type 1: clinical evaluations and in silico investigations
title Identification of compound heterozygous patients with primary hyperoxaluria type 1: clinical evaluations and in silico investigations
title_full Identification of compound heterozygous patients with primary hyperoxaluria type 1: clinical evaluations and in silico investigations
title_fullStr Identification of compound heterozygous patients with primary hyperoxaluria type 1: clinical evaluations and in silico investigations
title_full_unstemmed Identification of compound heterozygous patients with primary hyperoxaluria type 1: clinical evaluations and in silico investigations
title_short Identification of compound heterozygous patients with primary hyperoxaluria type 1: clinical evaluations and in silico investigations
title_sort identification of compound heterozygous patients with primary hyperoxaluria type 1: clinical evaluations and in silico investigations
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625645/
https://www.ncbi.nlm.nih.gov/pubmed/28969594
http://dx.doi.org/10.1186/s12882-017-0719-y
work_keys_str_mv AT kanounhouda identificationofcompoundheterozygouspatientswithprimaryhyperoxaluriatype1clinicalevaluationsandinsilicoinvestigations
AT jarrayafaical identificationofcompoundheterozygouspatientswithprimaryhyperoxaluriatype1clinicalevaluationsandinsilicoinvestigations
AT maalejbayen identificationofcompoundheterozygouspatientswithprimaryhyperoxaluriatype1clinicalevaluationsandinsilicoinvestigations
AT lahianiamina identificationofcompoundheterozygouspatientswithprimaryhyperoxaluriatype1clinicalevaluationsandinsilicoinvestigations
AT mahfoudhhichem identificationofcompoundheterozygouspatientswithprimaryhyperoxaluriatype1clinicalevaluationsandinsilicoinvestigations
AT maknifatma identificationofcompoundheterozygouspatientswithprimaryhyperoxaluriatype1clinicalevaluationsandinsilicoinvestigations
AT hachichajamil identificationofcompoundheterozygouspatientswithprimaryhyperoxaluriatype1clinicalevaluationsandinsilicoinvestigations
AT fakhfakhfaiza identificationofcompoundheterozygouspatientswithprimaryhyperoxaluriatype1clinicalevaluationsandinsilicoinvestigations